Hepatitis C Antiviral Drugs Reduce Liver Cancer Risk

The single leading cause of hepatocellular carcinoma (HCC) around the world is chronic infection with hepatitis C virus (HCV).

Other risk factors associated with an increased incidence of HCC include liver fibrosis, cirrhosis, increased age, male sex, diabetes, obesity, smoking, excessive alcohol intake, hepatitis B virus (HBV) co-infection, and HCV genotype 3 infection.

Prior to the recent availability of direct-acting antivirals (DAAs) for the treatment of HCV, interferons were a mainstay of therapy. Evidence suggests that interferon-based therapy to achieve sustained virologic response (SVR) in patients with chronic HCV dramatically reduces the risk of HCC, although it may take many years to fully realize that risk reduction.
Recent studies have reached disparate conclusions regarding the impact of DAAs on the risk of HCC among patients with HCV who have achieved SVR. As a result, Gilead Sciences, Inc., a biopharmaceutical company responsible for bringing a number of DAAs to the market, funded an investigation to further elucidate the relationship between DAAs and the risk of HCC.
Amanda Singer, PhD, MPH, researcher at Gilead and lead study author, and colleagues explained the rationale for their investigation, “The seriousness of HCC as a potential treatment-related outcome, contrasted with the serious implications of withholding HCV treatment from sick patients due to a potentially unfounded concern of an increased risk of HCC development after DAA therapy, warrants further investigation.”
Click here to continue reading on MD Magazine.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Cancers of the lung, breast, prostate, and colon are most common in adults aged 85 years and older.
Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.